Alzamend Neuro, Inc. — Director's Dealing 2021

Sep 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-09-08

Reporting Person: Horne William B. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-08	Common Stock	M	100000	—	Acquired	100000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-08	Stock Options (Right to Buy)	$0.004	M	100000	Disposed	2026-04-29	Common Stock (100000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$1.50	2029-11-25	Common Stock (250000)	250000	Direct
Stock Options (Right to Buy)	$1.50	2029-11-25	Common Stock (250000)	250000	Direct

Footnotes

F1: This transaction was effected pursuant to Rule 16b-3 with shares of common stock received upon the exercise of stock options.

F2: The stock options exercised in this transaction were fully vested and exercisable as of the transaction date.

F3: The stock options vest ratably over thirty-six (36) months beginning on the date of grant.

F4: None of these performance-based stock options are vested or exercisable.